Cardiol Therapeutics Inc Class A (CRDL.TO) faced a significant drop of 5.88% in its stock price during the last trading session, closing at CA$1.44.
In a market that often rewards innovation and growth, Cardiol Therapeutics Inc Class A is struggling to maintain its footing. The stock's recent decline highlights the volatility that can accompany biotech investments, especially in a sector influenced by clinical trial outcomes and market sentiment.
Advertisement
Earn cash back with a smarter spending account
Open a KOHO account and start earning on everyday purchases — no annual fee on the base plan.
Cardiol Therapeutics Inc Class A
CRDL.TO
CRDL.TO
Cardiol Therapeutics Inc Class A
WealthAwesomeMarket cap
$192.50M
52W high
$2.33
52W low
$1.23
1W change
-6.29%
Beta
0.51
Analyst Price Targets
Based on analyst covering CRDL
Wall Street analysts forecast CRDL stock price to rise 265.9% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$6.00
+265.9% Upside
Current Price
C$1.64
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on CRDL's historical volatility
30-Day Vol
50.9%
Annualized
90-Day Vol
60.2%
Annualized
Trend (90d)
-50.0%
Annualized drift
90d Mean
C$1.37
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$1.55 | C$1.30 – C$1.84 |
| 60 trading days | C$1.46 | C$1.14 – C$1.87 |
| 90 trading days | C$1.37 | C$1.01 – C$1.86 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Investor takeaway: Investors should be cautious with Cardiol Therapeutics, especially given its recent performance and the absence of significant news to support a rebound.
CRDL.TO down 5.88% in one day
The stock's market cap now stands at CA$176 million, reflecting investor caution amid ongoing clinical developments.
Bull case
Despite the recent downturn, Cardiol Therapeutics has some promising clinical trials underway. If these trials succeed, they could drive future growth for the company.
Bear case
However, the lack of recent positive news and the significant drop in stock price may indicate investor concerns about the company's future prospects and the competitive landscape.
Recent Performance Overview
Advertisement
Cardiol Therapeutics Inc Class A's stock fell sharply by 5.88% in the last trading session, closing at CA$1.44. This decline reflects broader investor concerns, particularly in the biotech sector, where stock prices can be highly sensitive to trial results and market sentiment.
Market Sentiment and Future Outlook
The recent drop in CRDL.TO's stock price comes amid a lack of significant news that could boost investor confidence. While the company has ongoing clinical trials, the absence of immediate positive developments may be weighing on investor sentiment. For more insights on Cardiol's market position, check out our detailed analysis on CRDL.TO.
What Investors Should Consider
Investors should exercise caution when considering Cardiol Therapeutics as part of their portfolio. The recent performance suggests volatility, and without positive news to counterbalance the current trend, potential investors may want to wait for clearer signals before diving in. For further information on the company's activities, visit our page on Cardiol Therapeutics.
Advertisement
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
